FTC Says Boehringer Should Cough Up Pay-For-Delay Docs
The U.S. Federal Trade Commission asked a D.C. federal court Friday not to allow Boehringer Ingelheim Pharmaceuticals to delay producing documents related to a pay-for-delay suit over stroke prevention drug Aggrenox...To view the full article, register now.
Already a subscriber? Click here to view full article